Inova Emergency Research Fund 2023 Donor Impact Report

2023 DONOR IMPACT REPORT Inova's Emergency Research Fund

AT THE FOREFRONT: COVID-19 RESEARCH On March 6, 2020, Inova's first COVID-19 patient was admitted, and on March 15, Inova's Advanced Lung Disease team led by Steven Nathan, MD was asked to lead all COVID-19 related research.

As a result, the Emergency Research Fund was created to address the growing need to support research operations in 2020 and beyond.

Inova's "COVID-19 Eradication Squad"

Inova team members recognized that COVID-19 would be the challenge of our time – with years of training and education preparing them for this moment.

PAGE 1

WHAT YOUR DONATION MADE POSSIBLE Your gifts and donations $1.03 provided a continuous and source of funding to MILLION predictable support short to medium term RAISED positive impact on patient care.

"Over the past three years, the utilization of this fund has ensured financial viability of the research enterprise by focusing only on studies that have immediate or mediumterm impact on patient care.

Your generosity allows for the continuation of innovative research at Inova."

STEVEN NATHAN, MD MEDICAL DIRECTOR, INOVA’S ADVANCED LUNG DISEASE PROGRAM AND LUNG TRANSPLANT PROGRAM AND COVID-19 RESEARCH EFFORTS PAGE 2

YOUR IMPACT: RESEARCH STUDIES

81 Total clinical research studies dedicated to COVID-19 research from 2020-2023

Even at the height of the pandemic, Inova team members of all specialties were aware of the importance of focusing research efforts on the long-term implications of COVID-19 on the cardiovascular and pulmonary systems.

Over the last three years, research studies have been approved in clinical areas such as: Cancer Heart and Vascular Medicine Musculoskeletal PAGE 3

Neurosciences Pediatrics Surgery Women's

Research Teams You have advanced the work of research investigators across Inova Health System.

Journals and Publications You have expanded the knowledge of the research community and preserved innovative work.

2,800+ Enrolled Clinical Trial Participants You supported and helped to ensure the rights, safety and welfare of the research participants were protected.

PAGE 4

LEADING THE FIELD Research and sharing of findings are integral to Inova's mission to ensure better patient outcomes and are highly resource-intensive.

$101,000 Average Requested You have reduced financial barriers for researchers by helping to operationalize their studies.

PAGE 5

PAGE 4

Examples of Inova's Research Publications and Partnerships Collection and Storage of Biospecimens and Clinical Data for Research in Patients with, suspected, and recovered coronavirus disease

Regular Exercise is Associated with Low Fatigue Levels and Good Functional Outcomes PostCOVID-19: A Prospective Observational Study.

SARS-CoV2 Seroprevalence in PSV Hematology-Oncology Patients

Immune response to COVID-19 infection in patients with metabolic syndrome Prevalence of COVID-19 in young children – an understudied potential reservoir for community infection Assessment and Care of Sequelae of Coronavirus (COVID-19) Infection Through a Multidisciplinary Approach

PAGE 1

Decreasing thrombotic risk during COVID-19 ECMO and beyond

PAGE 6

PAGE 02

THANK YOU! Your support was critical to our ability to respond quickly and to help save thousands of lives in our community and across the nation.

Because of your ongoing support, we are continuing to learn more about COVID-19 and its long-term effects on patients in our community.

Thank you for placing your trust in us to advance this groundbreaking work.